The FDA is delaying its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for multiple myeloma in earlier lines of treatment, and it plans to hold a public meeting with outside experts to discuss.
The regulator was originally expected to make a decision by…
Click here to view original post
